Table 4. Published papers and abstracts documenting toxicity and surgical morbidity in preoperative chemoradiation studies using cetuximab.

	No of pts*	Cetuximab	Oxali	irinotecan	RT dose	G3/G4 diarrhoea	SEPSIS	Anastom leak	Reoperation
Chung 2006 (45)	20	Yes	No	No	50.4 Gy/28#/38	2/20 (10%)	NS	NS	NS
Machiels 2007 (46)	40	Yes	No	No	45 Gy/25#/33	6/40 (15%)	5/40 (12.5%)	NS	5/40 (12.5%)
Rodel 2008 (47)	48	Yes	Yes	No	50.4 Gy/28#/38	9/48 (19%)	2/48 (4%)	5/48 (11%)	5/48 (11%)
Hofheinz 2006 (48)	20	Yes	No	Yes	50.4 Gy/28#/38	2/10 (20%)	2/20 (10%)	3/20 (15%)	NS
Horisberger 2009 (49)	50	Yes	No	Yes	50.4 Gy/28#/38	15/50 (30%)	NS	8/50 (16%)	NS
Bertolini 2007 (50)	40	Yes	No	No	50 Gy/25#/33-50.4 Gy/28#/38	3/40 (7.5%)	1/40 (5%)	1/40 (5%)	1/40 (5%)
Hong 2007 (51)	10	Yes	No	Yes	50.4 Gy/28#/38	1/40 (5%)	NS	NS	NS
Cabebe 2008 (52)	23	Yes	First 10 pts	No	50.4 Gy/28#/38	4/23 (17%)	NS	NS	NS
Eisterer 2009 (53)	28	Yes	No	No	45 Gy/25#/33	4/28 (15%)	NS	NS	NS
Velenik 2009 (54)	37	Yes	No	No	45 Gy/25#/33	4/37 (11%)	NS	NS	NS
Kim 2011 (55)	40	Yes	No	Yes	50.4 Gy/28#/38	2/40 (5%)	NS	1/40	NS
Dewdney 2012 (58)	78	Yes	No	No	50.4 Gy/28#/38	10/78 (16%)	NS	NS	NS
Sun 2012 (57)	63	yes	No	No	50.4 Gy/28#/38	23/63 (38.5%)
Total	497				45-50.4 Gy	82/494 (16.6%)

*number entering study; **number having had surgery; ***using tumour regression grading not yp; NS, not specified in paper; RT, radiotherapy; G3/G4, grade 3 and grade 4 toxicity